Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Karl Schoenafinger is active.

Publication


Featured researches published by Karl Schoenafinger.


British Journal of Pharmacology | 1999

Release of nitric oxide from endothelial cells stimulated by YC‐1, an activator of soluble guanylyl cyclase

Paulus Wohlfart; Tadeusz Malinski; Hartmut Ruetten; Ursula Schindler; Wolfgang Linz; Karl Schoenafinger; Hartmut Strobel; Gabriele Wiemer

In this study we examined the endothelium‐dependent effect of YC‐1–a benzyl indazole derivative which directly activates soluble guanylyl cyclase (sGC)–on vascular relaxation and nitric oxide (NO) and guanosine‐3′,5′‐cyclic monophosphate (cyclic GMP) in endothelial cells. In preconstricted rat aortic rings with intact endothelium, YC‐1 produced a concentration‐dependent relaxation. However, the concentration response curve was shifted rightward to higher concentrations of YC‐1, when (i) the aortas were pre‐treated with L‐NG‐nitroarginine methylester (L‐NAME) or (ii) the endothelium was removed. Incubation of bovine aortic endothelial cells (BAEC) with YC‐1 produced a concentration‐dependent NO synthesis and release as assessed using a porphyrinic microsensor. Pre‐incubating cells with L‐NAME or with 8‐bromo‐cyclic GMP decreased this effect indicating that the YC‐1 stimulation of NO synthesis is due to an activation of nitric oxide synthase, but not to an elevation of cyclic GMP. No direct effect of YC‐1 on recombinant endothelial constitutive NO synthase activity was observed. The YC‐1 stimulated NO release was reduced by 90%, when extracellular free calcium was diminished. In human umbilical vein endothelial cells (HUVEC), YC‐1 stimulated intracellular cyclic GMP production in a concentration‐ and time‐dependent manner. Stimulation of cyclic GMP was greater with a maximum concentration of YC‐1 compared to calcium ionophore A23187. Similar effects were observed in BAEC and rat microvascular coronary endothelial cells (RMCEC). When HUVEC and RMCEC were pre‐treated with L‐NG‐nitroarginine (L‐NOARG), the maximum YC‐1 stimulated cyclic GMP increase was reduced by 50%. These results indicate, that beside being a direct activator of sGC, YC‐1 stimulates a NO‐synthesis and release in endothelial cells which is independent of elevation of cyclic GMP but strictly dependent on extracellular calcium. The underlying mechanism needs to be determined further.


Archive | 2003

Pyridazinone derivatives as gsk-3beta inhibitors

Swen Hoelder; Thorsten Naumann; Karl Schoenafinger; David William Will; Hans Matter; Guenter Mueller; Suisse Dominique Le; Bernard Baudoin; Thomas Rooney; Franck Halley; Gilles Tiraboschi


Archive | 2003

Heterocyclically substituted benzoylureas, method for their production and their use as medicaments

Karl Schoenafinger; Elisabeth Defossa; Dieter Kadereit; Roedern Erich Von; Thomas Klabunde; Hans-Joerg Burger; Andreas Herling; Karl-Ulrich Wendt


Archive | 2003

Acyl-4-carboxyphenylurea derivatives, method for production and use thereof

Elisabeth Defossa; Dieter Kadereit; Karl Schoenafinger; Thomas Klabunde; Hans-Joerg Burger; Andreas Herling; Karl-Urlich Wendt; Roedern Erich Von; Alfons Enhsen; Joerg Rieke-Zapp


Archive | 2004

Novel cyanopyrrolidides, methods for the production thereof, and use of the same as medicaments

Karl Schoenafinger; Holger Wagner; Gerhard Jaehne; Holger Gaul; Christian Buning; Georg Tschank; Ulrich Werner


Archive | 2004

Novel cyano thiazolides, methods for the production thereof, and use thereof as a medicament

Holger Wagner; Karl Schoenafinger; Gerhard Jaehne; Holger Gaul; Christian Buning; Georg Tschank; Ulrich Werner


Archive | 2003

Heterocyclically substituted benzoylureas, process for their preparation and their use as pharmaceuticals

Karl Schoenafinger; Elisabeth Defossa; Dieter Kadereit; Erich von Roedern; Thomas Klabunde; Hans-Joerg Burger; Andreas Herling; Karl-Ulrich Wendt


Archive | 2006

4-BENZIMIDAZOL-2-YL-PYRIDAZINE-3-ONE-DERIVATIVES, PRODUCTION AND USE THEREOF IN MEDICAMENTS

Karl Schoenafinger; Swen Hoelder; David William Will; Hans Matter; Guenther Mueller; Martin Bossart


Archive | 2005

Substituted bicyclic 8-pyrrolidino-xanthines and use thereof as inhibitors of the dipeptidyl peptidase iv

Karl Schoenafinger; Gerhard Jaehne; Elisabeth Defossa; Lothar Schwink; Holger Wagner; Christian Buning; Georg Tschank; Ulrich Werner


Archive | 2005

SUBSTITUTED 8-AMINOALKYLTHIO-XANTHINES, AND THE USE THEREOF AS INHIBITORS OF THE DIPEPTIDYL PEPTIDASE IV

Karl Schoenafinger; Gerhard Jaehne; Elisabeth Defossa; Guenter Billen; Christian Buning; Georg Tschank; Ulrich Werner

Collaboration


Dive into the Karl Schoenafinger's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge